Sangamo TherapeuticsNASDAQ: SGMO

Sangamo Therapeutics (SGMO) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.34 per share a year ago.

Positive Type B meeting held with FDA, whereby U.S. agency stated that the phase 1/2 STAAR study using isaralgagene civaparvovec targeting Fabry Disease patients would be enough for Accelerated Approval. The global Fabry Disease treatment market size is expected to be worth $3.34 billion by 2030. Data from the phase 1/2 STARR study, using isaralgagene civaparvovec targeting patients with Fabry Disease, is expected in the first half of 2025.

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025.

Sangamo Therapeutics, Inc.'s stock surged after positive updates on two lead assets, giro-vec and STAC-BBB, with potential for significant milestone payments and partnerships. The upcoming isa-vec deal could be transformative, potentially securing Sangamo's financial stability and pushing its valuation towards $1 billion. Despite recent gains, high volatility and financial risks make SGMO a speculative investment, suitable only for risk-tolerant investors.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Amy Pooler - Head of Research Nathalie Dubois-Stringfellow - Chief Development Officer Conference Call Participants Nicole Germino - Truist Securities Gena Wang - Barclays Yanan Zhu - Wells Fargo Maury Raycroft - Jefferies Lisa Walter - RBC Operator Good afternoon, and welcome to the Sangamo Therapeutics Second Quarter 2024 Teleconference Call. Please be advised that today's conference is being recorded.

Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.37 per share a year ago.

Sangamo Therapeutics (NASDAQ: SGMO ) stock is rising higher on Tuesday after the clinical-stage genomic medicine company announced a new license agreement. Sangamo Therapeutics has signed a license agreement Genentech for the development of intravenously administered genomic medicines to treat certain neurodegenerative diseases.

When small-cap biotech stocks go on a tear, many investors pay attention. Little-known company Sangamo Therapeutics (NASDAQ: SGMO ) is making waves today, with SGMO stock up more than 40% at the time of this writing.

Sangamo Therapeutics, Inc. is almost out of cash, and as such, at risk of bankruptcy.  Therefore, investing in this company is not a good idea for most investors. 3 of its assets have updates coming over the next 1–6 months that could realistically bring in a combination of ~$1B of cash & milestones over the next 12–18 months. Due to its history of burning cash and not being able to get a drug approved yet, Sangamo Therapeutics's stock price closed Monday, 07/22/24 at $0.395/s or a valuation of ~$82M.